NascaCell announces a collaboration agreement with Aventis

14-Sep-2004

Munich. NascaCell announced that it has entered into a collaboration with Aventis. Under a framework agreement NascaCell will provide Aventis with access to its proprietary aptamer technology. Aventis is a global pharmaceutical company with a commercial presence in approximately 85 countries and products available in more than 170. Aventis has been part of the Sanofi-Aventis group since August 20, 2004.

"We are delighted to have the opportunity of this collaboration with Aventis. It further establishes the use of aptamers for accelerated target validation" said Dr. Andreas Jenne, CEO of NascaCell.

Aptamers are synthetic oligonucleotides that are able to bind to target proteins with high affinity and specificity. Because of the small molecule-like binding characteristics of aptamers, they typically show strong inhibition of protein function. NascaCell offers aptamers as tools for accelerated target validation and drug discovery.

Dr. Lucio A.A. van Rooijen at van Rooijen & Partners mediated the business deal.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances